NCT06511570View on ClinicalTrials.gov

A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 25, 2024

Primary Completion Date

September 17, 2024

Study Completion Date

September 17, 2024

Conditions
Alzheimer Disease
Interventions
DRUG

sabirnetug (ACU193)

sabirnetug by intravenous infusion

COMBINATION_PRODUCT

Sabirnetug + rHuPH20

sabirnetug + rHuPH20 by subcutaneous injection

Trial Locations (1)

78217

Worldwide Clinical Trials, San Antonio

Sponsors
All Listed Sponsors
lead

Acumen Pharmaceuticals

INDUSTRY

NCT06511570 - A Study Comparing the Safety, Tolerability, and Pharmacokinetics of Sabirnetug IV and Sabirnetug + rHuPH20 SC in Healthy Participants | Biotech Hunter | Biotech Hunter